Head to Head Comparison: Pulse Biosciences (NASDAQ:PLSE) and Competitive Technologies (OTCMKTS:CTTC)

Competitive Technologies (OTCMKTS:CTTC) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Profitability

This table compares Competitive Technologies and Pulse Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Competitive Technologies	N/A	N/A	N/A
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Earnings and Valuation

This table compares Competitive Technologies and Pulse Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Competitive Technologies	N/A	N/A	N/A	N/A	N/A
Pulse Biosciences	$350,000.00	9,462.00	-$72.78 million	($1.18)	-40.55

Competitive Technologies has higher earnings, but lower revenue than Pulse Biosciences.

Institutional and Insider Ownership

77.0% of Pulse Biosciences shares are held by institutional investors. 17.5% of Competitive Technologies shares are held by insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Competitive Technologies and Pulse Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Competitive Technologies	0	0	0	0	0.00
Pulse Biosciences	1	0	4	0	2.60

Pulse Biosciences has a consensus price target of $45.25, indicating a potential downside of 5.43%. Given Competitive Technologies’ higher possible upside, equities analysts clearly believe Competitive Technologies is more favorable than Pulse Biosciences.

Summary

Pulse Biosciences beats Competitive Technologies on 5 of the 9 factors compared between the two stocks.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.